Intensive Care Medicine

, Volume 38, Issue 4, pp 642–648 | Cite as

Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition

  • Sara S. Cheng
  • Kristen Nordenholz
  • David Matero
  • Nathan Pearlman
  • Martin McCarter
  • Csaba Gajdos
  • Christine Hamiel
  • Angela Baer
  • Elizabeth Luzier
  • Zung Vu Tran
  • Timothy Olson
  • Kelly Queensland
  • Ryan Lutz
  • Paul Wischmeyer
Original

Abstract

Purpose

To assess coagulation status and factor Xa inhibition in surgical intensive care unit (ICU) patients administered prophylactic unfractionated heparin for venous thromboembolism (VTE) prophylaxis.

Methods

We conducted a randomized, single-blind study at a tertiary academic medical center. Included were patients 18 years and older admitted to the surgical ICU directly after major abdominal surgery. Exclusion criteria included significant bleeding risk, preoperative anticoagulation, or history of heparin-induced thrombocytopenia. Patients were randomized to two regimens for VTE prophylaxis: standard of care unfractionated heparin, 5,000 units subcutaneously three times daily (SQH) versus unfractionated heparin via intravenous infusion, titrated to an activated partial thromboplastin time of 40–45 s (IVH). Blood samples were taken prior to surgical incision on day 0 and daily for 5 days after surgery. Samples were analyzed for factor Xa inhibition and viscoelastic whole blood clotting parameters (Sonoclot analyzer).

Results

A total of 50 patients were randomized to either SQH or IVH. The majority of patients had cancer. Patients in the SQH group had no detectable peak anti-factor Xa (aFXa) activity for 5 days after surgery, while patients in the IVH group had statistically elevated levels compared to the SQH group on days 3–5. SQH patients demonstrated a hypercoagulable profile on Sonoclot, while IVH patients displayed a normal profile.

Conclusions

Standard of care subcutaneous dosing of unfractionated heparin for VTE prophylaxis in surgical ICU patients leads to subtherapeutic levels of factor Xa inhibition.

Keywords

Intensive care unit Surgery Cancer Anticoagulation Venous thromboembolism Prophylaxis Sonoclot 

Notes

Acknowledgments

We would like to gratefully acknowledge Gina Haeussner, MD for her help with data collection, and Sabrina Espinoza for her administrative support. We also thank Jon Henderson for Sonoclot product support. This work was supported in part by a Resident Fellowship Grant from the Foundation for Anesthesia Education and Research.

Conflicts of interest

None.

References

  1. 1.
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:381S–453SPubMedCrossRefGoogle Scholar
  2. 2.
    Geerts W, Selby R (2003) Prevention of venous thromboembolism in the ICU. Chest 124:357S–363SPubMedCrossRefGoogle Scholar
  3. 3.
    Leizorovicz A, Mismetti P (2004) Preventing venous thromboembolism in medical patients. Circulation 110:IV13–IV19Google Scholar
  4. 4.
    Phung OJ, Kahn SR, Cook DJ, Murad MH (2011) Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 140:374–381Google Scholar
  5. 5.
    The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011) Dalteparin versus unfractionated heparin in critically Ill patients. N Engl J Med 364:1305–1314Google Scholar
  6. 6.
    Zalpour A, Kroll MH, Afshar-Kharghan V, Yusuf SW, Escalante C (2011) Role of factor Xa inhibitors in cancer-associated thrombosis: any new data? Adv Hematol 2011:196135PubMedGoogle Scholar
  7. 7.
    Cook DJ, Crowther MA (2010) Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med 38:S76–S82PubMedCrossRefGoogle Scholar
  8. 8.
    Fries D (2011) Thrombosis prophylaxis in critically ill patients. Wien Med Wochenschr 161:68–72PubMedCrossRefGoogle Scholar
  9. 9.
    Mayr AJ, Dunser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W (2002) Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 105:201–204PubMedCrossRefGoogle Scholar
  10. 10.
    Robinson S, Zincuk A, Strom T, Larsen TB, Rasmussen B, Toft P (2010) Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 14:R41PubMedCrossRefGoogle Scholar
  11. 11.
    Brancazio LR, Roperti KA, Stierer R, Laifer SA (1995) Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 173:1240–1245PubMedCrossRefGoogle Scholar
  12. 12.
    Gallus AS, Hirsh J, Tutle RJ, Trebilcock R, O’Brien SE, Carroll JJ, Minden JH, Hudecki SM (1973) Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 288:545–551PubMedCrossRefGoogle Scholar
  13. 13.
    Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L (2000) Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The association of non-university affiliated intensive care specialist physicians of France. Am J Respir Crit Care Med 161:1109–1114PubMedGoogle Scholar
  14. 14.
    Cade JF (1982) High risk of the critically ill for venous thromboembolism. Crit Care Med 10:448–450PubMedCrossRefGoogle Scholar
  15. 15.
    Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314PubMedCrossRefGoogle Scholar
  16. 16.
    Bergqvist D, Lindblad B (1985) A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg 72:105–108PubMedCrossRefGoogle Scholar
  17. 17.
    Rommers MK, Van der Lely N, Egberts TC, van den Bemt PM (2006) Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 10:R93PubMedCrossRefGoogle Scholar
  18. 18.
    Zenahlikova Z, Kvasnicka J, Kudrnova Z, Sudrova M, Brzezkova R, Mazoch J, Malikova I, Vyborny J, Erhart D, Pecen L (2009) FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients. Clin Appl Thromb Hemost 16:584–590Google Scholar
  19. 19.
    Dorffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Buller HR, Levi M (2002) Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359:849–850PubMedCrossRefGoogle Scholar
  20. 20.
    Ganter MT, Hofer CK (2008) Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 106:1366–1375PubMedCrossRefGoogle Scholar

Copyright information

© Copyright jointly held by Springer and ESICM 2012

Authors and Affiliations

  • Sara S. Cheng
    • 1
  • Kristen Nordenholz
    • 2
  • David Matero
    • 2
  • Nathan Pearlman
    • 4
  • Martin McCarter
    • 4
  • Csaba Gajdos
    • 4
  • Christine Hamiel
    • 1
  • Angela Baer
    • 1
  • Elizabeth Luzier
    • 1
  • Zung Vu Tran
    • 3
  • Timothy Olson
    • 5
  • Kelly Queensland
    • 6
  • Ryan Lutz
    • 1
  • Paul Wischmeyer
    • 1
  1. 1.Department of AnesthesiologyUniversity of Colorado School of MedicineAuroraUSA
  2. 2.Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraUSA
  3. 3.Department of Preventive Medicine and BiometricsUniversity of Colorado School of MedicineAuroraUSA
  4. 4.Department of SurgeryUniversity of Colorado School of MedicineAuroraUSA
  5. 5.Department of MedicineUniversity of Colorado School of MedicineAuroraUSA
  6. 6.Department of AnesthesiologyUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations